Recurrent Clostridioides difficile infections are a major challenge for long term care facilities with a population which is at risk of multiple recurrences despite standard of care antibiotics. There is a need to adopt a different approach by restoring the gut flora to normal and thereby obviating the conditions for C. difficile spores to grow and cause disease. The nursing home setting is a particularly difficult setting due to the proximity of residents, the pressure on nursing staff and the multiple risk factors such as antibiotic and proton pump use being present. Live Biotherapeutic Products may be an "old/new" approach to managing and reducing recurrence of CDI.
No takes yet. Share an insight, caveat, or question.
Glenn S. Tillotson (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: